Mild cognitive impairment

The Behavioral Neurology of Dementia

Volumn , Issue , 2009, Pages 172-187

  Kelley, Brendan J ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859305366     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511581410.013     Document Type: Chapter

References (68)

1. Petersen RC. Mild Cognitive Impairment: Aging to Alzheimer’s Disease. Oxford: Oxford University Press; 2003.
2. Petersen RC, Doody R, Kurz A et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58(12):1985-1992.
3. Petersen RC, Smith GE, Waring SC et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56(3):303-308.
4. Sloane PD, Zimmerman S, Suchindran C et al. The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23:213-231.
5. Gauthier S, Reisberg B, Zaudig M et al. Mild cognitive impairment. Lancet 2006;367(9518):1262-1270.
6. Lopez OL, Jagust WJ, DeKosky ST et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol 2003;60(10):1385-1389.
7. Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: longterm course of four clinical subtypes. Neurology 2006; 67(12):2176-2185.
8. Graham JE, Rockwood K, Beattie BL et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349 (9068):1793-1796.
9. Unverzagt FW, Gao S, Baiyewu O et al. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology 2001;57(9): 1655-1662.
10. Bennett DA, Wilson RS, Schneider JA et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59(2):198-205.
11. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001;56(1):37-42.
12. Hanninen T, HallikainenM, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand 2002;106(3):148-154.
13. Boeve B, McCormick J, Smith G et al. Mild cognitive impairment in the oldest old. Neurology 2003;60(3): 477-480.
14. Petersen R, Roberts R, Knopman D et al. Prevalence of mild cognitive impairment in a population-based study. Neurology 2007;68(Suppl 1):A237.
15. Jungwirth S, Weissgram S, Zehetmayer S, Tragl KH, Fischer P. VITA: subtypes of mild cognitive impairment in a community-based cohort at the age of 75 years. Int J Geriatr Psychiatry 2005;20(5):452-458.
16. Di Carlo A, Lamassa M, Baldereschi M et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology 2007; 68(22):1909-1916.
17. Das SK, Bose P, Biswas A et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 2007;68(23):2019-2026.
18. Larrieu S, Letenneur L, Orgogozo JM et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59(10):1594-1599.
19. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256(3):183-194.
20. Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256(3):240-246.
21. Mueller SG, Weiner MW, Thal LJ et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15(4):869-877, xi-xii.
22. Daly E, Zaitchik D, Copeland M et al. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 2000;57(5):675-680.
23. Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352(23):2379-2388.
24. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Mild cognitive impairment in different functional domains and incident Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005;76(11):1479-1484.
25. Fischer P, Jungwirth S, Zehetmayer S et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007;68(4):288-291.
26. Hunderfund AL, Roberts RO, Slusser TC et al. Mortality in amnestic mild cognitive impairment: a prospective community study. Neurology 2006;67(10): 1764-1768.
27. Jack CR, Jr., Petersen RC, Xu YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52(7):1397-1403.
28. Jack CR, Jr., Shiung MM, Weigand SD et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65(8):1227-1231.
29. Devanand DP, Pradhaban G, Liu X et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007; 68(11):828-836.
30. DeCarli C, Frisoni GB, Clark CM et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007;64(1):108-115.
31. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261(5123):921-923.
32. Aggarwal NT, Wilson RS, Beck TL et al. The apolipoprotein E epsilon4 allele and incident Alzheimer’s disease in persons with mild cognitive impairment. Neurocase 2005;11(1):3-7.
33. Tierney MC, Szalai JP, Snow WG et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996;46(1):149-154.
34. Petersen RC, Smith GE, Ivnik RJ et al. Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 1995;273(16):1274-1278.
35. Jak AJ, Houston WS, Nagel BJ, Corey-Bloom J, Bondi MW. Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. Dement Geriatr Cogn Disord 2007;23(6):282-289.
36. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278(16): 1349-1356.
37. Galasko D, Chang L, Motter R et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55(7):937-945.
38. Galasko D, Clark C, Chang L et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 1997;48(3):632-635.
39. Growdon JH. Biomarkers of Alzheimer disease. Arch Neurol 1999;56(3):281-3.
40. Sunderland T, Wolozin B, Galasko D et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 1999;46(6):750-755.
41. Stefani A, Martorana A, Bernardini S et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 2006;251(1-2):124-128.
42. Buerger K, Teipel SJ, Zinkowski R et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59(4):627-629.
43. Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 2006;129(Pt 11):3035-3041.
44. Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5(3):228-234.
45. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68(9):666-669.
46. Graff-Radford NR, Crook JE, Lucas J et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64(3):354-362.
47. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. [See comment.] Lancet Neurol 2006;5(8):655-660.
48. Small GW, Mazziotta JC, Collins MT et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273(12):942-947.
49. Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334(12):752-758.
50. Drzezga A, Grimmer T, Riemenschneider M et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005;46(10):1625-1632.
51. Anchisi D, Borroni B, Franceschi M et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62(11):1728-1733.
52. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306-319.
53. Small GW, Kepe V, Ercoli LM et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355(25):2652-2663.
54. Markesbery WR, Schmitt FA, Kryscio RJ et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006;63(1):38-46.
55. Morris JC, Storandt M, Miller JP et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58(3):397-405.
56. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64(5):834-841.
57. Petersen RC, Parisi JE, Dickson DW et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006;63(5):665-672.
58. Jicha GA, Parisi JE, Dickson DW et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006; 63(5):674-681.
59. Petersen RC. Mild cognitive impairment continuum. Lifelong Learn Neurol 2007;13(2):15-38.
60. Gold M, Francke S, Nye JS et al. Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment. Neurobiol Aging 2004;25(Suppl 2):S521.
61. Feldman HH, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the In DDEx study. Lancet Neurol 2007;6(6):501-512.
62. Thal LJ, Ferris SH, Kirby L et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30(6):1204-1215.
63. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003;2(8):646-653.
64. Petersen RC. MCI treatment trials: failure or not? Lancet Neurol 2007;6(6):473-475.
65. Petersen RC, Stevens JC, Ganguli M et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9): 1133-1142.
66. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3(6):343-353.
67. Rovio S, Kareholt I, Helkala EL et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol 2005; 4(11):705-711.
68. Petersen RC, O’Brien J. Mild cognitive impairment should be considered for DSM-V. J Geriatr Psychiatry Neurol 2006;19(3):147-154.